disodium;2-(1,3-dioxoinden-2-yl)quinoline-6,8-disulfonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: disodium;2-(1,3-dioxoinden-2-yl)quinoline-6,8-disulfonate
• 化学式: C18H9NNa2O8S2
• 分子量: 477.4
• InChiKey: FZUOVNMHEAPVBW-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -4.79
• 重原子数：
  31
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  178
• 氢给体数：
  0
• 氢受体数：
  9

ADMET

毒理性

• 解毒与急救

/SRP:/ 立即急救：确保已经进行了充分的中和。如果患者停止呼吸，请开始人工呼吸，最好使用需求阀复苏器、球囊阀面罩设备或口袋面罩，按训练操作。如有必要，执行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果患者呕吐，让患者向前倾或将其置于左侧（如果可能的话，头部向下），以保持呼吸道畅通，防止吸入。保持患者安静，维持正常体温。寻求医疗帮助。 /毒物A和B/

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 基本治疗：建立专利气道（如有需要，使用口咽或鼻咽气道）。如有必要，进行吸痰。观察呼吸不足的迹象，如有需要，协助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿，如有必要，进行治疗……。监测休克，如有必要，进行治疗……。预期癫痫发作，如有必要，进行治疗……。对于眼睛污染，立即用水冲洗眼睛。在运输过程中，用0.9%的生理盐水（NS）持续冲洗每只眼睛……。不要使用催吐剂。对于摄入，如果患者能够吞咽、有强烈的干呕反射且不流口水，则用温水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……。在去污后，用干燥的无菌敷料覆盖皮肤烧伤……。/毒药A和B/

/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 高级治疗：对于无意识、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。考虑使用药物治疗肺水肿……。对于严重的支气管痉挛，考虑给予β激动剂，如沙丁胺醇……。监测心率和必要时治疗心律失常……。开始静脉输注D5W /SRP: "保持开放"，最低流量/。如果出现低血容量的迹象，使用0.9%生理盐水（NS）或乳酸林格氏液。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象……。使用地西泮或劳拉西泮治疗癫痫……。使用丙美卡因氢氯化物协助眼部冲洗……。 /Poisons A and B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

人类暴露研究/重复侮辱贴片测试喹啉染料，D & C Yellow No. 10（酸黄No. 3）和D & C Yellow No. 11（溶剂黄No. 33）表明，前者的浓度高达1000 ppm没有诱导迟发型接触超敏反应，而D & C Yellow No. 11的20 ppm和10 ppm浓度在人类志愿者小组成员中诱导了迟发型超敏反应。这种染料的5 ppm测试没有明确导致超敏反应。两名使用含有D & C Yellow No. 11的肥皂条出现过敏性反应的人在使用这种染料被替换为D & C Yellow No. 10的肥皂条时没有反应。

/HUMAN EXPOSURE STUDIES/ Repeat insult patch testing of the quinoline dyes, D & C Yellow No. 10 (Acid Yellow No. 3) and D & C Yellow No. 11 (Solvent Yellow No. 33) demonstrated that concentrations as high as 1,000 ppm of the former induced no delayed contact hypersensitivity, whereas, concentrations of 20 ppm and 10 ppm of D & C Yellow No. 11 induced delayed hypersensitivity reactions in human volunteer panelists. No definitive hypersensitivity resulted from testing with 5 ppm of this dye. 2 persons who had been demonstrated to have reacted allergically to the use of a soap bar that contained D & C Yellow No. 11 did not react to the ad libitum use of a soap bar in which this dye was replaced with D & C Yellow No. 10.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

/HUMAN EXPOSURE STUDIES/ 喹啉染料D&C黄色11号被添加到标准测试系列中。在88名使用1%聚乙二醇测试的患者中，有四人显示出无法解释的阳性测试反应。一名患者在14天后出现了“爆发”反应。在再次挑战中，他对稀释至0.00001%的反应。与化学相关且常用的食品色素喹啉黄（E 104）同时反应，表明存在交叉敏感性。

/HUMAN EXPOSURE STUDIES/ The quinoline color D & C Yellow No. 11 was added to a standard test series. Of 88 patients tested with 1% in PEG, four showed unexplained positive test reactions. One patient had a "flare-up" reaction after 14 days. At rechallenge he reacted to a dilution down to 0.00001%. Simultaneous reaction with the chemically related commonly used food color Quinoline Yellow (E 104) suggests cross-sensitivity.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

黄色喹啉在 rats 中的摄取、命运和排泄进行了研究。在孤立灌注的肝脏中，70% 的剂量在 3 小时内排入胆汁中。在麻醉动物静脉注射后得到类似结果。当通过灌胃给药时，4-5 小时内只有大约 1% 在胆汁和尿液中排泄。口服给大鼠的黄色喹啉被定量排泄，主要排泄途径为粪便。大鼠从胃肠道吸收的黄色喹啉非常少。没有发现代谢的证据。

The uptake, fate and excretion of quinoline yellow, a coloring in sweets and soft drinks, in the rat were studied. In the isolated perfused liver, 70% of the dose was excreted into the bile within 3 hr. Similar results were obtained after i.v. injection into anesthetized animals. When given by gavage, only approximately 1% was excreted in bile and urine within 4-5 hr. Quinoline yellow administered orally to rats was quantitatively excreted, the excretion being mainly fecal. ... Very little quinoline yellow is absorbed from the gastrointestinal tract of the rat. No evidence of metabolism was obtained.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

喹啉黄在大鼠和狗的胃肠道的吸收程度很小，大多数口服给药的剂量以原形被排泄。

Quinoline Yellow is absorbed from the gastro-intestinal tract to only a small extent in rats and dogs, and most of an orally administered dose is excreted unchanged.

来源:Hazardous Substances Data Bank (HSDB)

文献信息

• Leave-in color conditioner
  申请人：Pollack George

  公开号：US20050198746A1

  公开（公告）日：2005-09-15

  The invention is directed to novel hair dye compositions, novel leave-in conditioners, and novel leave-in conditioners with a hair coloring effect. Hair dye compositions, leave-in conditioners, and leave-in conditioners with hair coloring effect may include a styrene/vinylpyrrolidone copolymer emulsion.

  本发明涉及新型染发剂组合物、新型留香护发素以及具有染发效果的新型留香护发素。染发剂组合物、留香护发素和具有染发效果的留香护发素可能包括苯乙烯/吡咯烷酮共聚物乳液。
• Bleach activators and method for the production thereof
  申请人：Pegelow Ulrich

  公开号：US20070197416A1

  公开（公告）日：2007-08-23

  Bleach activator compatibility with bleach-sensitive dyestuffs can be improved in accordance with various embodiments of the invention including methods for producing coated bleach activators which methods comprise: granulating at least one bleach activator with at least one binding agent to form a granulated material; coating the granulated material with a solution or dispersion of at least one complexing agent to form a coated granulated material; and drying the coated granulated material.

  漂白剂激活剂与对漂白剂敏感的染料的相容性可以根据发明的各种实施方式进行改善，包括生产涂层漂白剂激活剂的方法，该方法包括：将至少一种漂白剂激活剂与至少一种粘合剂颗粒化以形成颗粒材料；用至少一种络合剂的溶液或分散液对颗粒材料进行涂层，以形成涂层颗粒材料；并干燥涂层颗粒材料。
• Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
  申请人：BABUL Najib

  公开号：US20120178771A1

  公开（公告）日：2012-07-12

  The present invention is directed to oral, therapeutically effective pharmaceutical compositions of buprenorphine and it pharmaceutically acceptable salts and the use thereof, including delayed onset and controlled release dosage forms. The present invention is also directed delayed onset, rapid release dosage forms and delayed onset, extended release dosage forms of oral buprenorphine which provide robust efficacy and reduced potential for abuse and misuse.

  本发明涉及布洛芬静脉注射剂的制备方法，其特点在于提供了一种口服的、治疗有效的布洛芬药物组合物，包括布洛芬及其药学上可接受的盐，并且包括延迟发挥和控制释放的剂型。本发明还涉及口服布洛芬的延迟发挥、快速释放和延迟发挥、持续释放剂型，这些剂型提供了强大的疗效，并减少了滥用和误用的潜在风险。
• HAIR DYE OR COSMETIC MATERIAL, PRETREATMENT AGENT AND HAIR DYEING METHOD
  申请人：KANEBO, LTD.

  公开号：EP0634161A1

  公开（公告）日：1995-01-18

  A hair dye consisting of a hair resisting antibody fixed by a coloring material of a high bulk factor, in which the coloring material is composed of an inorganic pigment, water-soluble coloring matter or water-insoluble coloring matter, or possibly a complex of these coloring substances and a macromolecular support. Since this hair dye gives an excellent and fast color to hair uniquely, the skin is neither contaminated nor stimulated, and the feel and texture of hair are improved.

  一种染发剂，由高体积系数的着色材料固定的头发抗性抗体组成，其中着色材料由无机颜料、水溶性着色物质或水不溶着色物质组成，也可能是这些着色物质和高分子支持物的复合物。由于这种染发剂能使头发迅速上色，既不会污染皮肤，也不会刺激皮肤，同时还能改善头发的触感和质感。
• A powder composition and a cosmetic composition containing said powder composition
  申请人：Kosé Corporation

  公开号：EP0931537A2

  公开（公告）日：1999-07-28

  A powder composition comprising, a copolymer containing (A) an organopolysiloxane monomer, one or more kinds of monomer selected from a group composed by (B) a monomer containing nitrogen group, a monomer possessing a polyoxyalkylene group, a monomer possessing a polylactone group, a monomer possessing a hydroxyl group and a monomer possessing an anionic group and a powder. Further, a powder dispersion in oil comprising said copolymer, powder and oil, and a cosmetic composition containing them. Said powder composition and a powder dispersion in oil have a less cohesion of powder particles and is superior in a dispersing ability and a dispersion stability; and the cosmetic composition which contains said powder composition has a good stability and gives an excellent sensation at the actual use.

  一种粉末组合物，包括含有(A)有机聚硅氧烷单体的共聚物、一种或多种选自(B)含氮基团的单体、具有聚氧亚烷基的单体、具有聚内酯基团的单体、具有羟基的单体和具有阴离子基团的单体组成的组的单体以及粉末。此外，还包括上述共聚物、粉末和油在油中的粉末分散体，以及含有它们的化妆品组合物。所述粉末组合物和粉末在油中的分散体的粉末颗粒凝聚力较小，在分散能力和分散稳定性方面具有优势；含有所述粉末组合物的化妆品组合物具有良好的稳定性，在实际使用时具有极佳的感觉。